Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 14
Licensing Agreements 15
Merck Enters into Licensing Agreement with Ra Pharma 15
Equity Offering 17
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 17
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 18
Ra Pharma Prices IPO for USD91 Million 20
Ra Pharmaceuticals Inc – Key Competitors 22
Ra Pharmaceuticals Inc – Key Employees 23
Ra Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 08, 2018: Ra Pharmaceuticals reports second quarter 2018 financial results 25
May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 26
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 28
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results 31
May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 33
Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 34
Corporate Communications 36
Sep 25, 2018: Ra Pharma names Aoife M. Brennan, M.B., B.Ch., to Board of Directors 36
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer 37
Government and Public Interest 38
Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 38
Product News 39
06/24/2017: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association 39
05/18/2017: Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association 40
Product Approvals 41
Jul 31, 2017: Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 41
Clinical Trials 42
Sep 28, 2018: Ra Pharma reports positive data from Phase lb trial of zilucoplan 42
Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program 43
Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program 44
May 17, 2018: Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association 46
Feb 12, 2018: Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria 47
Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment 49
Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients 50
Dec 04, 2017: Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria 51
Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis 53
Jun 27, 2017: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH 54
Jun 21, 2017: Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH 55
Apr 26, 2017: Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 14
Merck Enters into Licensing Agreement with Ra Pharma 15
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 17
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 18
Ra Pharma Prices IPO for USD91 Million 20
Ra Pharmaceuticals Inc, Key Competitors 22
Ra Pharmaceuticals Inc, Key Employees 23
List of Figures
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10